ArticleFrontiers in genetics2025
Unveiling disulfidptosis-linked lncRNA signatures: insights into the immune microenvironment and drug responsiveness in oral squamous cell carcinoma.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Oral squamous cell carcinoma (OSCC) has a highly incidence rate and mortality rate all over the world. Hitherto, there are limited studies on survival significance between disulfidptosis-related lncRNAs (DRLs) and OSCC. Therefore, this study was conducted to investigate the potential role of these DRLs and provide some theoretical support in the clinical treatment of OSCC. Methods: OSCC-related lncRNAs and disulfidptosis-related genes (DRGs) were retrieved from public databases. Using Pearson correlation, machine learning, and expression profiling, we identified differentially expressed DRLs (DE-DRLs), developed a DE-DRLs-based risk model and independent prognostic nomogram, performed immunological and tumor microenvironment analyses to explore DE-DRLs regulatory mechanisms, predicted potential drugs for OSCC, and validated bioinformatics findings. Results: In this study, 9 DE-DRLs were identified that correlated with OSCC. The risk model and nomogram showed good clinical utility for assessing the likelihood of OSCC occurrence. Patients exhibiting elevated levels of eosinophils, activated natural killer (NK) cells, or naïve CD4 Conclusion: Our study identified 9 DE-DRLs correlated with OSCC, which will be a personalized prediction tool for prognosis and immune responses in OSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.